The clinical facilities of the two companies stretch across the United States and Europe to China and India. The technologies include a broad range of state-of-the-art computerized cognitive tests and batteries forming an unequalled library of tests for discovering drug effects and providing assessments optimized for specific compounds and patient groups. The full spectrum of cognitive drug development services provided by the two companies includes trial design and planning clinical development programs; site selection, study implementation and supervision; and data management, statistical analysis and report writing.
The scientific expertise comes from combining the leading international experts of the two companies, each with 20 to 40 years experience in cognitive drug development across different therapeutic areas .These opinion leaders include Dr Steven Ferris, Professor of Psychiatry at the New York University School of Medicine, a leader in clinical trials for aging and dementia, and Chief Scientific Officer of NetMet; Dr. Thomas Crook, a pioneer in cognitive assessment and drug development, and Dr Tonmoy Sharma, a leading expert in schizophrenia and cognition.
Net Met's Chief Operating Officer, Dr Thomas Crook, said: "Major international pharmaceutical companies and small innovative biotechnology companies are developing new treatments for a number of disorders that affect cognition. Such disorders arise not only from
'"/>
18-Jan-2005